About Integrin alpha-10
Integrin alpha-10 (ITGA10) is a protein
from Homo sapiens identified by UniProt accession
O75578, 1167 residues long.
MolForge cross-references it against 0 known binders and
99 disease associations.
Target properties
| Protein name | Integrin alpha-10 |
|---|
| UniProt accession | O75578 |
|---|
| Gene | ITGA10 |
|---|
| Organism | Homo sapiens |
|---|
| Length | 1167 residues |
|---|
| Molecular weight | — |
|---|
| EC numbers | — |
|---|
| Target class | UNCLASSIFIED |
|---|
| Subcellular location | — |
|---|
| Keywords | — |
|---|
Druggability
Target tractability assessment (Open Targets + pocket analysis). No approved drug
| Druggability tier | MEDIUM |
|---|
| Druggability score | — |
|---|
| Pocket score | — |
|---|
| Max clinical phase | — |
|---|
Disease associations (99)
Diseases linked to this target (Open Targets).
- neurodegenerative disease · score 0.31
- myeloid white cell count · score 0.30
- breast adenocarcinoma · score 0.24
- thyroid gland adenocarcinoma · score 0.18
- glioblastoma multiforme · score 0.17
- cutaneous melanoma · score 0.14
- lung adenocarcinoma · score 0.10
- type 2 diabetes mellitus · score 0.08
- Upington disease · score 0.06
- Gollop-Wolfgang complex · score 0.05
3D Structure (1)
Experimental (PDB) and predicted (AlphaFold) structures for this protein.
| Structure | Source | Method | Mean pLDDT | Resolution (Å) |
|---|
| AF-O75578-F1 | alphafold | PREDICTED | 85.20 | — |
Amino-acid sequence (1167 residues)
MELPFVTHLF LPLVFLTGLC SPFNLDEHHP RLFPGPPEAE FGYSVLQHVG GGQRWMLVGA PWDGPSGDRR GDVYRCPVGG AHNAPCAKGH LGDYQLGNSS HPAVNMHLGM SLLETDGDGG FMACAPLWSR ACGSSVFSSG ICARVDASFQ PQGSLAPTAQ RCPTYMDVVI VLDGSNSIYP WSEVQTFLRR LVGKLFIDPE QIQVGLVQYG ESPVHEWSLG DFRTKEEVVR AAKNLSRREG RETKTAQAIM VACTEGFSQS HGGRPEAARL LVVVTDGESH DGEELPAALK ACEAGRVTRY GIAVLGHYLR RQRDPSSFLR EIRTIASDPD ERFFFNVTDE AALTDIVDAL GDRIFGLEGS HAENESSFGL EMSQIGFSTH RLKDGILFGM VGAYDWGGSV LWLEGGHRLF PPRMALEDEF PPALQNHAAY LGYSVSSMLL RGGRRLFLSG APRFRHRGKV IAFQLKKDGA VRVAQSLQGE QIGSYFGSEL CPLDTDRDGT TDVLLVAAPM FLGPQNKETG RVYVYLVGQQ SLLTLQGTLQ PEPPQDARFG FAMGALPDLN QDGFADVAVG APLEDGHQGA LYLYHGTQSG VRPHPAQRIA AASMPHALSY FGRSVDGRLD LDGDDLVDVA VGAQGAAILL SSRPIVHLTP SLEVTPQAIS VVQRDCRRRG QEAVCLTAAL CFQVTSRTPG RWDHQFYMRF TASLDEWTAG ARAAFDGSGQ RLSPRRLRLS VGNVTCEQLH FHVLDTSDYL RPVALTVTFA LDNTTKPGPV LNEGSPTSIQ KLVPFSKDCG PDNECVTDLV LQVNMDIRGS RKAPFVVRGG RRKVLVSTTL ENRKENAYNT SLSLIFSRNL HLASLTPQRE SPIKVECAAP SAHARLCSVG HPVFQTGAKV TFLLEFEFSC SSLLSQVFVK LTASSDSLER NGTLQDNTAQ TSAYIQYEPH LLFSSESTLH RYEVHPYGTL PVGPGPEFKT TLRVQNLGCY VVSGLIISAL LPAVAHGGNY FLSLSQVITN NASCIVQNLT EPPGPPVHPE ELQHTNRLNG SNTQCQVVRC HLGQLAKGTE VSVGLLRLVH NEFFRRAKFK SLTVVSTFEL GTEEGSVLQL TEASRWSESL LEVVQTRPIL ISLWILIGSV LGGLLLLALL VFCLWKLGFF AHKKIPEEEK REEKLEQ
Explore Integrin alpha-10 with MolForge
Find binders, run structure-based screening, and map this target across
diseases and approved drugs with our AI-powered platform.
Browse all targets